CHMP rec­om­mends against Mi­rati's KRAS ri­val, in fa­vor of Pfiz­er's RSV vac­cine, oth­er drugs

The Eu­ro­pean Med­i­cines Agency’s hu­man med­i­cines com­mit­tee (CHMP) rec­om­mend­ed against con­di­tion­al au­tho­riza­tion for Mi­rati’s KRAS G12C in­hibitor Kraza­ti in non-small cell lung can­cer this week, while giv­ing the thumbs-up to 14 oth­er drugs, in­clud­ing Pfiz­er’s RSV vac­cine.

CHMP said on Fri­day that there were un­cer­tain­ties about how well Kraza­ti (ada­gra­sib) worked, adding that “com­pre­hen­sive da­ta for this med­i­cine were not yet avail­able” and cri­te­ria for a con­di­tion­al mar­ket­ing au­tho­riza­tion were un­met.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER